Market Research Blog – Page 1140 – New Product Development

Dystrophic Epidermolysis Bullosa Management Market Projected to Reach USD 787.8 Million in 2033, Growing at 5.7% CAGR Through 2033

The global dystrophic epidermolysis bullosa (DEB) management market is on a positive growth trajectory, with an expected market value of USD 452.37 million in 2023. The market is projected to exhibit a compound annual growth rate (CAGR) of 5.7% from 2023 to 2033.

This growth is primarily driven by the high prevalence of skin diseases and the increasing incidence of dystrophic epidermolysis bullosa, a rare but severe genetic condition that causes fragile skin prone to blistering. The rising demand for effective management solutions and ongoing advancements in treatment options are key factors contributing to the market’s expansion.

Dystrophic epidermolysis bullosa is a rare but severe genetic skin condition that causes fragile skin prone to blistering. The high incidence of this condition, combined with growing awareness and advancements in treatment options, are significant factors propelling the market’s growth.

Treatment for dystrophic epidermolysis bullosa involves a wound care regimen that integrates contemporary wound care techniques while eliminating factors that can irritate and inflame the skin. Dermatologists recommend adhering to strict personal hygiene habits and thoroughly moisturizing after treatments for dystrophic epidermolysis bullosa to promote healing of blisters without further damage or infection. Aqueous disinfectants are highly effective in treating DEB, and micro-adhesive silicone-based wound care is particularly useful for individuals with tough skin areas like elbows, shoulders, and trunks. Topical antibiotic ointments are expected to become the primary treatment for curing wounds and preventing the spread of infection in the future.

Various methods are being researched to treat EB, including the use of gene-corrected iPS cells from the patient’s own body, gene editing technologies, and polymer-mediated DNA delivery methods. Protein replacement therapies have been successful in treating several genetic diseases and could potentially be used to treat EB. A protein therapy approach involving intravenous and intradermal injections of recombinant collagen VII appears to be promising in treating DEB at the preclinical level, but further testing and development are necessary to determine its usefulness in treating patients.

Key Takeaways:

By 2023, global dystrophic epidermolysis bullosa management sales are expected to reach US$ 452.37 Million.
Antibiotics for dystrophic epidermolysis bullosa management are expected to grow 32% market share between 2023 and 2033.
Hospital pharmacies for the dystrophic epidermolysis bullosa management market are projected to grow at a CAGR of 3.4% from 2023 to 2033.
A market share of 23% is forecasted for the North American dystrophic epidermolysis bullosa management market.
European markets are projected to grow at a CAGR of 2.6% during the forecast period.

“The development of stem cell therapy, approval of new topical and oral medicines, and development of diagnostic devices will support the growth of dystrophic epidermolysis bullosa management market.” comments a Future Market Insights analyst.

Competitive Landscape :

Diagnostic techniques are increasingly being developed and researched in parallel as they advance. Several companies will likely expand their product lines, acquire other firms, or merge in the near future as new techniques and treatment emerge.

Abeona Therapeutics Inc. announced the completion of the final 6-month follow-up visit of its primary Phase 3 VIITAL trial of EB-101, the company’s targeted cell therapy investigation for dystrophic epidermolysis bullosa (RDEB). In order to lock the database within two to three weeks after the last patient’s final visit, Abeona has been verifying and preparing the data in real-time. As a result of the VIITAL study, Abeona intends to seek approval from the U.S. Food and Drug Administration (FDA) for EB-101 for the treatment of RDEB patients.
Researchers from Relief Therapeutics will test APR-TD011 on the effects of bacterial colonization on epidermolysis bullosa (EB) wounds in a pilot study. A chemical with strong antimicrobial properties, hypochlorous acid, is the active ingredient in the treatment. Buying Nexodyn helps cleanse and moisturize cuts, burns, and abrasions as well as acute wounds. In a trial that has been initiated by the investigator (NCT05533866), 15 patients with junctional EB or dystrophic EB and wounds infected with Staphylococcus aureus and/or Pseudomonas aeruginosa bacteria will be enrolled soon.

Key players:

Castle Creek Biosciences, Amryth Pharma, Krystal Biotech, Abeona Therapeutics, BridgeBio, Phoenix Tissue Repair, Wings Therapeutics, InMed Pharmaceuticals, Inc., Regenerx Biopharmaceuticals Inc., Holostem Terapie Avanzate S.r.l

More insights available

In North America and Europe, where there is a greater prevalence of the condition and higher levels of healthcare spending, there are more treatment options available. These options include wound care management, pain management, and gene therapy. The U.S. Food and Drug Administration (FDA) has approved several products for Dystrophic Epidermolysis Bullosa treatment, including a topical gel that helps to manage blistering and wound healing.

A Old Full Report Analysis Click Here

Key Segments:

By Disease Type:

Dominant Dystrophic Epidermolysis Bullosa (DDEB)
Recessive Dystrophic Epidermolysis Bullosa (RDEB)

By Drug Class:

Antibiotics
Corticosteroids
Opioid Analgesics
Anticonvulsant

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Podiatry Service Market Set for Steady Growth, Projected to Reach USD 6,077.7 Million by 2034 at a 3.6% of CAGR

The global podiatry service market is poised for steady growth, with an anticipated compound annual growth rate (CAGR) of 3.6% over the next decade. According to the latest market analysis, the market, valued at USD 4,845.2 million in 2024, is projected to expand to USD 6,077.7 million by 2034. The market was valued at USD 4,720.0 million in 2023.

The market is continuously expanding and includes services and treatments for illnesses, deformities, and injuries of the foot and ankle. The use of the MDT method to offer patients with integrated and comprehensive care has accelerated the acceptance of podiatry services in hospitals.

In addition, the podiatry association’s efforts to raise awareness, as well as existing hospitals and clinics seeking to improve the accessibility and availability of services, have aided market growth and awareness. The market for these services is growing in lockstep with the rise in diabetic, obese, and geriatric populations, as foot issues disproportionately affect these groups.

The market’s expansion is being fuelled by reasons such as the surge in disposable income, proactive attitude, and increased knowledge about foot care. The expansion of technology and trained resources, as well as initiatives by podiatry groups to increase the use and assist practitioners, have increased awareness of the services.

The rising incidence of foot disorders, particularly in the diabetic and elderly populations with 6.3% and 24%, respectively, as well as increased awareness and preventative approaches to children’s foot problems, are driving the market expansion. Furthermore, sportspersons’ use of specialized sports foot and ankle services for the treatment of foot and ankle injuries demonstrates the market potential for podiatry services in the sports area.

Competitive Analysis

In addition, the podiatry association’s efforts to raise awareness, as well as existing hospitals and clinics seeking to improve the accessibility and availability of services, have aided market growth and awareness. The market for these services is growing in lockstep with the rise in the diabetic, obese, and geriatric population, as foot issues disproportionately affect these groups.

Some of the recent developments of key podiatry service providers are as follows:

In May 2022, Go 4-D, a firm established in Canada, stated that it would focus on data-driven and patient-centric research to aid in the creation of 3D-printed custom-made orthotics.

In April 2022, Kaiser Permanente announced a US$ 1 Billion investment to expand its reach in the United States by creating new clinics and acquiring companies to provide podiatry treatments.

More Valuable Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Podiatry Services market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023-2033.

The study reveals essential insights by Type (General Podiatry, Podiatry surgery, Sports Podiatry and Podopediatrics), by Facility (Hospitals & Outpatient departments, Podiatry Offices/Clinics and Homecare & Telemedicine), across key regions (North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa).

A Old Full Report Analysis Click Here

Market Segments Covered in Podiatry Services Market Analysis

By Type:

General Podiatry
Podiatry surgery
Sports Podiatry
Podopediatrics

By Facility:

Hospitals & Outpatient departments
Podiatry Offices/Clinics
Homecare & Telemedicine

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Prosthetics and Orthotics Market Expected to Surge to USD 12.2 Billion by 2033, Driven by 6% CAGR

Future Market Insights has unveiled a new report on the prosthetics and orthotics market, highlighting significant growth opportunities in the sector. The global market, valued at USD 6.5 billion in 2022, is projected to experience robust expansion, with an anticipated compound annual growth rate (CAGR) of 6% from 2023 to 2033. By the end of the forecast period, the market is expected to exceed USD 12.2 billion.

The report underscores the pivotal role of orthotics in driving market revenue, with this segment also expected to grow at a CAGR of approximately 6% over the next decade. This growth is fueled by advancements in prosthetic and orthotic technologies, increasing prevalence of orthopedic conditions, and a rising demand for personalized healthcare solutions.

Due to a range of benefits, including less pain and faster mobility recovery, upper limb orthotics accounted for the majority of the market. From 2021 to 2028, spinal orthotics is expected to grow at the fastest pace due to factors such as an increased incidence of spine injuries, a growing target population, and unhealthy lifestyles.

The rising senior demographic has become one of the main factors for the swelled demand for prosthetics and orthotics globally. According to the United Nations, the number of people aged 60 and over will more than double, from 962 million in 2017 to 2.1 billion in 2050. Elderly people are more vulnerable to such health conditions as osteoporosis and osteopenia, making them regular clients of orthopedic medications.

The increasing prevalence of osteosarcoma in young people and children is further upscaling the demand. The most common bone tumor in children is osteosarcoma. Osteosarcoma is typically treated with chemotherapy, surgery, and radiation. Post-operative treatment for patients recuperating from this procedure usually includes orthopaedic devices and prostheses.

In 2022, North America held a significant share of the global Prosthetics & Orthotics market. Government support for the Prosthetics and Orthotics sector’s development, a high level of awareness about cardiovascular and neurological disorders for an aging population, and increased awareness to spend on sports injuries are expected to propel the demand forward. Besides, easy access to high-quality medical facilities and attractive reimbursement policies are some of the key drivers of regional market growth.

Competitive Landscape

Ossur
Blatchford, Inc.
Fillauer LLC
Otto bock Healthcare GmbH
The Ohio Willow Wood Company
Ultraflex Systems
Steeper Group

Some of the recent developments of key Prosthetics and Orthotics providers are as follows:

In October 2022,Endolite announced that Linx, its fully integrated, microprocessor-controlled lower limb system has been awarded a German Design Award in the ‘Universal Design’ category.

A Old Full Report Analysis Click Here

Market Segments Covered in Prosthetics & Orthotics Market Analysis

By Type:

Prosthetics
- Upper Extremity
- Lower Extremity
- Liners
- Sockets
- Modular Components
Orthotics
- Upper Limb
- Lower Limb
- Spinal

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Cytokine Release Syndrome Management Market Set to Reach USD 44.6 Billion by 2023, Projected to Grow at 6.7% CAGR Through 2033

The global cytokine release syndrome (CRS) management market is on track for substantial growth, with an estimated market value of USD 23.32 billion in 2023. According to the latest projections, the market is expected to exhibit a compound annual growth rate (CAGR) of 6.7% from 2023 to 2033.

This significant growth is attributed to the increasing incidence of autoimmune diseases and cancers, which are driving the demand for effective CRS management solutions. As the prevalence of these conditions continues to rise, the need for advanced therapies and management strategies for CRS is becoming more critical.

Cytokine release syndrome, a severe and potentially life-threatening condition, is often associated with immune therapies, such as CAR-T cell therapy, used in cancer treatment. As the use of these therapies expands, so too does the demand for effective CRS management solutions. This trend is expected to drive significant growth in the CRS management market over the next decade.

As cancer rates rise and treatment options for CRS increase, the market will continue to expand. For instance, Harpoon Therapeutics, Inc., is developing novel T-cell engagers in clinical trials. The 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans presents updated interim data from the Phase 1 clinical trial evaluating HPN217 in relapsed/refractory multiple myeloma (RRMM). Based on Harpoon’s proprietary TriTAC ® platform, HPN217 targets B-cell maturation antigens (BCMA) to bring patients’ own immune cells to the tumor.

FDA approvals of various therapeutics and drugs have further enhanced the market. Further studies and tests funded by the government will increase awareness of CRS management by clinical professionals. For instance, mosunetuzumab-axgb (Lunsumio; Genentech) was approved by the FDA for the treatment of adults with R/R follicular lymphoma. As of July 2022, mosunetuzumab had been granted priority review by the FDA for the treatment of R/R FL. High and durable responses were demonstrated in the phase 2 GO29781 study (NCT02500407), which supported the decision. The continued approval of this product is dependent on a confirmatory trial verifying clinical benefit since this is an accelerated approval.

Key Takeaways from the Market Study 

Globally, the cytokine release syndrome management market is expected to reach US$ 23.32 billion by 2023.
Hospitals for cytokine release syndrome management are expected to grow 32% market share between 2023 and 2033.
The market for Tumour Necrosis Factor-TNF is projected to grow by 2.9% from 2023 to 2033.
Cytokine release syndrome management in North America expanded with a market share of 17% during the forecast period.
According to forecasts, the arthritis therapeutics market accumulate a share of 19% over the next few years.

“Advances in immunotherapies, the approval of new drugs, and CAR T-cell therapies are expected to further accelerate the growth of the cytokine release syndrome management market.” comments a Future Market Insights analyst.

Competitive Landscape 

The development of innovative diagnostic techniques is becoming increasingly important for companies, which will probably lead to a number of firms expanding their product lines, acquiring other companies, or merging their companies in the near future, as many are likely to focus on developing new diagnostic techniques.

Kite announced that the Food and Drug Administration (FDA) has approved the addition of prophylactic corticosteroids to the prescribing information for Yescarta®. The label on Yescarta includes information to guide physicians in managing and possibly preventing side effects associated with chimeric antigen receptor (CAR) T-cell therapies. To maximize the chances of CAR T-cell therapy being beneficial to as many patients as possible, Kite has been working closely with physicians since Yescarta’s first approval in 2012. CAR T therapy research is also focused on expanding into new diseases and early treatment lines, while continuously enhancing the safety and efficacy of existing treatments.
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., reported stable response rates among 6 patients with relapsed/refractory AL amyloidosis using NXC-201. Six relapsed/refractory AL amyloidosis patients treated with NXC-201 have shown 100% complete response. Using clinical cancer research, 100% complete responses were observed; 100% organ responses were observed; and at 5.2 months, the duration of response was still unknown, resulting in an average reduction of 65% (2,656 pg/mL) in NT-proBNP from baseline. There was no grade 4 Cytokine Release Syndrome. ICANS neurotoxicity was not observed; NYHA stage improved by 2 stages.

Key Companies Profiled:

F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Novartis AG
Sanofi S.A
Pfizer Inc.
Bayer AG
Biocon
AbbVie Inc.
Johnson & Johnson Private Limited
Incyte Corporation
Swedish Orphan Biovitrum
Genentech

A Old Full Report Analysis Click Here

Key Segments Profiled in the Cytokine Release Syndrome Management Industry Survey?

By Cytokine Type:

Tumor Necrosis Factor-TNF
Interleukins-II
Interferons-IFN
Epidermal Growth Factor-EGF

By Therapeutic Application:

Cancer
Asthma
Airway Inflammation
Arthritis
Others

By Biomarker Type:

Interleukin-10
Interferon Gamma
Interleukin-6
Ferritin
Cluster of Differentiation-163

By Route of Administration:

Oral
Intravenous

By End User:

Hospitals
Specialty Clinics
Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Biosensors Market Poised for Robust Growth, Projected to Reach USD 24.5 Billion by 2033

Future Market Insights has released a comprehensive analysis of the biosensors market, revealing a substantial increase in market size and growth prospects. The global biosensors market was valued at USD 24.5 billion in 2022 and is anticipated to experience a significant upward trajectory with a compound annual growth rate (CAGR) of 9.5% from 2023 to 2033.

The market’s expansion is expected to be driven by advancements in biosensor technologies and increased applications across various sectors, including healthcare, environmental monitoring, and industrial processes. Among the different segments, medical biosensors are projected to be the highest revenue-generating category. This segment is expected to grow at an impressive CAGR of over 10.5% during the forecast period, reflecting the rising demand for advanced diagnostic and monitoring solutions in healthcare.

The biosensors market is being driven by an increase in chronic illnesses such as diabetes, an increase in biotechnology research and development, and an increase in demand for homecare equipment. The increased use of biosensors in glucose monitoring systems has resulted in market expansion. However, market growth is expected to be hampered by the high costs associated with these devices, as well as a lack of willingness to embrace new treatment devices. Improvements in biosensor technology, on the other hand, that add portability, are expected to drive market growth.

Nanotechnology-based biosensors are expected to be profitable in a variety of industries, including food analysis, imaging operations, and microbial activity monitoring. The market is consolidating as a result of the increasing popularity of medical equipment and customised drugs, as well as a greater demand for non-invasive biosensors and increased research collaboration and agreements among various producers.

Because of their ability to assess fitness as well as the onset and progression of illness, biosensors are widely used in home-based healthcare by patients. As a result, the market is expected to expand throughout the forecast period. A variety of non-medical activities, as well as technological advancement, are expected to broaden its applicability and, as a result, support its growth. Pregnancy testing, cholesterol testing, blood glucose testing, and drug detection are some of the healthcare services that are expected to have a positive market impact.

Competitive Analysis

Because of the increased demand for biosensors, global manufacturers are accelerating and improving their manufacturing processes by implementing cost-effective solutions. A few of the key players in the biosensors market include Bio-Rad Laboratories Inc., Medtronic, Abbott Laboratories, Biosensors International Group, Ltd., Pinnacle Technologies Inc., Ercon, Inc., DuPont Biosensor Materials, Johnson & Johnson, Koninklijke Philips N.V., LifeScan, Inc., QTL Biodetection LLC, Molecular Devices Corp., Nova Biomedical, Molex LLC, TDK Corporation, Zimmer & Peacock AS, and Siemens Healthcare.

Some of the recent developments of key Biosensors providers are as follows:

In January 2022, Roche and Sysmex agreed to a Global Business Partnership (GBP) to provide haematological diagnostic services. The new collaboration will use IT technology to improve clinical decision-making and the consumer experience. This long-running, fruitful collaboration is still going strong, providing haematological diagnostic improvements to labs worldwide.
In December 2020, Abbott announced that FreeStyle Libre 2, its next-generation sensor-based glucose monitoring device, has been approved by Health Canada for adults and children (4 years and older) with diabetes.

More Valuable Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Biosensors Market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023-2033.

The study reveals essential insights by Product Type (Medical, Food Toxicity, Bioreactor, Agriculture, Environment and Others), Technology (Thermal, Electrochemical, Piezoelectric and Optical), End-Use (Home Healthcare Diagnostics, PoC Testing, Food Industry, Research Laboratories and Security & Biodefence) and across key regions (North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa).

A Old Full Report Analysis Click Here

Market Segments Covered in Biosensors Market Analysis :

By Product Type:

Medical
- Cholesterol
- Blood Glucose
- Blood Gas Analyzer
- Pregnancy Testing
- Drug Discovery
- Infectious Disease
Food Toxicity
Bioreactor
Agriculture
Environment
Others

By Technology:

Thermal
Electrochemical
Piezoelectric
Optical

By End-Use:

Home Healthcare Diagnostics
PoC Testing
Food Industry
Research Laboratories
Security & Biodefense

By Region:

North America
Latin America
Europe
APAC
Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

PCSK9 Inhibitor Market to Surge with 21.5% Growth, Projected to Reach USD 15,140.3 Million by 2034

The global PCSK9 inhibitor market is set to experience substantial growth, with an estimated market size of USD 2,733.7 million in 2024, reflecting a year-over-year growth of 21.5%. The market is projected to expand at a robust compound annual growth rate (CAGR) of 18.7% throughout the forecast period, with total sales anticipated to reach approximately USD 15,140.3 million by 2034.

The market’s impressive growth trajectory is driven by increasing adoption of PCSK9 inhibitors for managing high cholesterol levels and advancements in cardiovascular disease treatment. Among the various segments, evolocumab is expected to dominate the PCSK9 inhibitor industry, holding a substantial value share of 71.3% in 2024.

Additionally, the inclisiran segment is forecasted to exhibit remarkable growth, with sales expanding at a staggering CAGR of 31.3% during the assessment period. This rapid expansion is attributed to the innovative nature of inclisiran and its growing acceptance in clinical settings.

PCSK9 inhibitors, a class of drugs designed to lower LDL cholesterol levels in patients who are at high risk of cardiovascular events, continue to gain traction in the healthcare industry due to their efficacy and potential to address unmet needs in cardiovascular care.

According to research, PCSK9 Inhibitors are effective at lowering cholesterol. PCSK9 Inhibitors are administered once or twice a month through injection under the skin, self-administration, or medical representation. As a result, the PCSK9 Inhibitors Market is expected to grow and increase significantly throughout the forecast period. The worldwide PCSK9 Inhibitors Market is expected to thrive in the future, with a substantially higher CAGR.

During the projected period, Europe is estimated to have the highest global PCSK9 Inhibitors Market share. This is owing to increased spending and better healthcare infrastructure in nations such as Germany, Italy, and Spain, which are the region’s major contributors to growth.

Key Takeaways from the Market Study

FMI projects the global PCSK9 Inhibitors market to expand at a 15.8% value CAGR by 2033
The global PCSK9 Inhibitors market is estimated at a market value of US$ 3 Billion
The global PCSK9 Inhibitors market is expected to garner a market value of US$ 13 Billion
Asia Pacific is expected to grow at a CAGR of 15% in the assessment period 2023-2033.
North America is expected to grow at a CAGR of 15.7% in the assessment period 2023-2033.
Europe is expected to grow at a CAGR of 15.3% in the assessment period 2023-2033.
The Repatha segment is expected to hold the largest market share for PCSK9 Inhibitors in the forecast period 2023-2033

“Asia Pacific is expected to have a significant market share. This is due to increased healthcare awareness, research activity, and government initiatives in the healthcare industry to create jobs in the region,” says an analyst at FMI.

Market Competition

New product registrations for early diagnosis, strategic alliances for mergers, acquisitions, marketing, a large distribution channel, and significant R&D investment are some of the primary strategies employed by notable organisations operating in the PCSK9 inhibitors Market. The top players in the PCSK9 inhibitors industry have been identified and characterised for their distinct business features. Key players in the PCSK9 Inhibitors market are Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam, AstraZeneca and Affiris.

Recent Developments:

In December 2022, the boards of directors of Horizon Therapeutics plc and Amgen Inc., announced that they have agreed on the terms of a cash offer for the Company by Pillartree Limited (“Acquirer Sub”), a newly formed private limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and under which Acquirer Sub will acquire the entirety of the Company’s issued and to be issued ordinary share capital.
In December 2022, Eli Lilly and Company announced that its purchase of Akouos, Inc. was completed successfully. The purchase broadens Lilly’s genetic medicines efforts to include Akouos’ portfolio of potential first-in-class adeno-associated viral gene treatments for the treatment of inner ear diseases such as sensorineural hearing loss.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the global PCSK9 Inhibitors market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of type (repatha, praluent, bococizumab and others), and application (clinical application, drug development and others), across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Key Players:

Amgen Plc.
Eli Lilly & Co.
Sanofi S.A
Pfizer Inc.
Novartis AG
Roche Diagnostics
Merck & Co. KGaA
Alnylam
AstraZeneca
Affiris

A Old Full Report Analysis Click Here

Key Segments Profiled in the PCSK9 Inhibitors Industry Survey

By Type:

Repatha
Praluent
Bococizumab
Others

By Application:

Clinical Application
Drug Development
Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Oncolytic Virus Cancer Therapy Market Poised for Rapid Growth, Projected to Reach USD 250 Million by 2033 at a 27% of CAGR

The global oncolytic virus cancer therapy market is set for exceptional growth, with an anticipated valuation of USD 22.86 million in 2023. According to recent market projections, the sector is expected to expand at a remarkable compound annual growth rate (CAGR) of 27% from 2023 to 2033, reaching an estimated market value of USD 250 million by the end of the forecast period.

This significant growth underscores the increasing interest and investment in innovative cancer therapies. Oncolytic virus therapy, which leverages genetically modified viruses to target and destroy cancer cells, is gaining traction due to its potential to revolutionize cancer treatment and improve patient outcomes.

Oncolytic virus cancer therapy, an innovative approach that leverages genetically modified viruses to selectively target and destroy cancer cells while sparing healthy tissues, is gaining significant traction in the oncology field. The substantial growth forecast underscores the increasing adoption of this therapy as a promising treatment option for various types of cancer.

Government agencies in developed and developing countries are conducting education programs to encourage people to seek early cancer diagnosis, which is expected to increase the number of patients who will be eligible for numerous new therapies.

Due to a significant increase in the number of companies that produce cancer medications, the Asia Pacific region will have the highest ownership stake in the oncolytic virus cancer market. The oncolytic virus therapy market is growing in revenue and earnings as countries such as China and Japan introduce breakthroughs into the market.

Because of the region’s high incidence of cancer, particularly melanoma cancer, North America is expected to be the most valuable region for the global oncolytic virus cancer market. Increased cancer incidences around the world are creating a positive outlook for the market. In line with this, the therapy’s widespread use in the treatment of a wide range of melanomas, including haematological malignancies, lymphoma, leukaemia, and myeloma, is boosting overall growth.

Key Takeaways from the Market Study

The number of articles on oncolytic virus therapy studies has increased by 395% in the last decade.
In 2022, Japan’s total oncolytic virus cancer market share was US$ 2 Million, and it is expected to rise during the study period.
North America is expected to grow at the fastest rate during the forecast period, with a CAGR of 29.5%.
In the United States in 2021, the market value for oncolytic virus therapies was US$ 8.5 Million
The global oncolytic virus cancer market is expected to be worth US$ 250 Million.

“As oncology takes a turn for the better, healthcare practitioners are implementing highly advanced ways of diagnosing and treating some of the most debilitating cancers, paving way for enhanced adoption of oncolytic virus cancer therapies,” remarks an FMI analyst.

Market Competition

Key players in the Oncolytic Virus Cancer market are Oncolytics Biotech Inc, Amgen Inc., Sorrento Therapeutics, Transgene SA, Daiichi Sankyo Company, Shanghai Sunway Biotech Co, Ltd, Takara Bio Inc., PsiOxus Therapeutics, SillaJen Inc., ViroCure.

Amgen, based in the United States, agreed to pay $3.7 billion for the biopharma firm ChemoCentryx in August 2022. As a result of this strategic initiative, Amgen will provide access to Tavneos, the company’s critical therapy that has received therapy confirmation in the EU and Japan. Amgen will be able to expand its reach and develop in regions such as Europe and Asia Pacific as a result of this acquisition.
In April 2021, Bristol Myers Squibb and PsiOxus Therapeutics enlarged their partnership to investigate PsiOxus Therapeutics’ cancer-killing virus. According to the contract, the collaboration will incorporate Bristol’s checkpoint reagent Opdivo and novel resource NG-641 in various types of tumors. PsiOxus’ oncolytic virus ‘enadenotucirev’ is the basis for NG-641.

A Old Full Report Analysis Click Here

Key Segments Profiled in the Oncolytic Virus Cancer Therapy Market Industry Survey

By Virus Type:

Genetically Engineered Oncolytic Viruses
- Herpes Simplex Virus
- Adenovirus
- Vaccinia Virus
Oncolytic Wild-type Viruses
- Reovirus
- Newcastle Disease Virus
- Vesicular Stomatitis Virus

By Application:

Solid Tumor
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Glioblastoma
Melanoma
- Hematological Malignancies
- Lymphoma
- Leukemia
- Myeloma

By End Use:

Hospitals
Specialty Clinics
Cancer Research Institutes

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Chronic Wound Care Market Forecasted to Reach USD 25,042.5 Million by 2033, with a CAGR of 3.8%

The global chronic wound care market is poised for significant growth, with expectations to rise at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2033. The market, valued at USD 17,272.4 million in 2023, is projected to increase to approximately USD 25,042.5 million by 2033.

In 2022, the chronic wound care market was valued at USD 16,689.3 million and is anticipated to exhibit a year-over-year growth of 3.5% in 2023. This upward trend reflects the growing demand for advanced wound care solutions and innovations in treatment methods.

Additionally, Indian Institute of Science researchers have created bandages that include magnetic nanofibers that can cure skin cancer non-invasively. Researchers at IISc have come up with a bandage that’s fabricated by electrospinning using a unique blend of nanoparticles. It has been demonstrated that real-time monitoring of wound parameters at the site of the wound is crucial for effective wound care using various sensing techniques, including physical and chemical sensors.

The development of technologies to monitor a variety of biomarkers affecting wound healing, such as temperature, pressure, pH, and infection status, has been a focus of considerable effort in recent years. On-demand and local drug delivery have been developed as advanced wound therapies to assist in the diagnosis and treatment of wounds.

The advancement of technology and innovative 3D techniques, along with trackers and apps, will allow consumers to monitor the healing process of their finger wounds. For instance, Heriot-Watt University researchers developed tiny sensors that track wound healing and speed using a bandage under a bandage. There have been many studies on wound biology, but little is known about the physicality’s that contribute to wound healing, especially at the microscale, where advancement occurs at sub-hair widths. Crichton writes that few studies have actually been conducted on wounds.

Key Takeaways from the Market Study 

The global market size for chronic wound care is estimated to reach US$ 15.98 Billion by 2023.
According to the forecast, the market is expected to grow by 7% between 2023 and 2033, reaching a total of US$ 31.46 billion by 2033.
Across all wound dressing categories in 2023, advanced wound dressings accounted for 54% of the total market value.
Chronic wound care in North America expanded with a market share of 33% in 2022.
According to forecasts, by 2023 the diabetic ulcer market will account for 38% of the total market value.

“As diabetic ulcers become more prevalent and new drugs and devices are approved, artificial intelligence and technology are expected to play a significant role in growing sensor-based bandages.” comments a Future Market Insights analyst.

Competitive Landscape 

Research and the development of innovative diagnostic techniques are expected to be the focus of many companies in the near future, resulting in the expansion of their product lines, the acquisition of other companies, and the merger of their businesses.

Healthium Medtech, based in Bengaluru, has introduced its new wound dressing portfolio Theruptor Novo to manage chronic wound care such as diabetic foot ulcers and leg ulcers. Healthium expands its portfolio of advanced wound dressing products with Theruptor Novo. Approximately 25% of diabetics will develop a foot ulcer during their lifetime. As a result of complications caused by untreated diabetic foot ulcers, almost 1 lakh amputations have been registered in India today. In addition to being painful and expensive, foot ulcers require a lot of treatment.
In an era when complex chronic wound care are on the rise, while access to wound care nurse specialists is becoming more challenging, HARTMAN USA and Corstrata announce their partnership to support home health and other in-home providers. Clinical expertise and evidence-based treatment protocols are essential to integrate advanced wound dressings with a successful wound care program. BerryDunn’s National Healthcare at Home Best Practices and Future Insights Study, published in recent months by top-50 accounting firm BerryDunn, indicates that wound-certified specialists are on staff at all of the top 10% of home health agencies with positive financial surpluses.

Key Companies Profiled:

Paracrine, Inc.
Oneness Biotech
Biotissue
Polarity TE
MediWound
Anterogen Co., Ltd.
TR Therapeutics
RHEACELL GmbH & Co.KG
Smith & Nephew
Kaken Pharmaceutical

Non-healing wounds involves a multi-disciplinary approach that may include wound debridement (removing dead or infected tissue), wound dressings, offloading (reducing pressure on the wound), and the use of advanced wound care products like growth factors or skin substitutes.

A Old Full Report Analysis Click Here

Key Segments Profiled in the Chronic Wound Care Market Industry Survey

Type:

Diabetic Ulcers
Pressure Ulcers
Venous Ulcers
Other Chronic Wounds

Product:

Advanced Wound Dressings
Wound Care Therapy
Active Therapy
Others

End User:

Hospital and Wound Care Centers
Homecare Settings
Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global HER2-Positive Gastric Cancer Market Set for Growth, Projected to Reach USD 1,779.8 Million by 2033 at a 3.5% of CAGR

The global HER2-positive gastric cancer market is on a promising growth trajectory, with a current valuation of USD 1,261.8 million in 2023. According to the latest market analysis, this sector is expected to expand at a compound annual growth rate (CAGR) of 3.5% over the next decade. By 2033, the market is projected to reach approximately USD 1,779.8 million.

This positive outlook is driven by significant advancements in healthcare technology and an increasing focus on targeted therapies. The development of innovative treatment options and improved diagnostic tools are expected to contribute to the market’s expansion.

This growth is largely driven by ongoing technological advancements in the healthcare sector, which are enhancing treatment options and improving patient outcomes for those diagnosed with HER2-positive gastric cancer. As research and development in targeted therapies continue to advance, the market is poised for sustained growth over the next decade.

The anticipated expansion reflects the critical importance of innovation in the treatment of gastric cancer, particularly for patients with HER2-positive tumors, who require specialized and effective therapeutic approaches. The market’s growth underscores the healthcare industry’s commitment to improving cancer care and addressing the needs of patients worldwide.

For instance, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers. Additionally, the increasing number of special designations for drugs in the pipeline is also expected to fuel the growth of the market.

North America dominates the HER 2 positive gastric cancer market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.

Key Takeaways from the Market Study

As of 2023, the HER2 positive gastric cancer market was valued at US$ 1261.8 Million
From 2023 to 2033, the HER2 positive gastric cancer industry is poised to grow at an 3.5% CAGR
By 2033, the HER2 positive gastric cancer market is slated to reach a valuation of US$ 1779.8Million
Based on therapy, the targeted therapy segment dominated the global market in 2023 with a revenue share of over 55.4%.
China is poised to yield a CAGR of 3.2% with respect HER2 positive gastric cancer in 2033

“Technological advancement in healthcare and increase in the prevalence of gastric cancer is expected to radically transform the HER 2 positive gastric cancer market in the coming years,” comments an analyst at FMI.

Competitive Landscape

AstraZeneca
Bayer
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd
Hutchison Medipharma
LintonPharm
Shanghai Henlius Biotech
Sanofi
Pfizer
Novartis AG

Manufacturers and players functional in the global HER 2 positive gastric cancer market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.

In September 2022 -Shanghai Henlius Biotech, Inc announced a phase 1 clinical trial of the company’s HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanised monoclonal antibody(mAb) injection, has been completed in patients with HER2 overexpressing advanced solid tumours. The results of this study demonstrated the good safety and tolerability of HLX22.
In January 2022 — LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that it has completed the enrollment of stage 1 of the global phase III trial (clinicaltrials.gov: NCT04222114). This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis (GCPC).

A Old Full Report Analysis Click Here

Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey

HER2 Positive Gastric Cancer Market by Therapy:

Chemotherapy
Immunotherapy
Radiation Therapy
Targeted Therapy

HER2 Positive Gastric Cancer Market by Stage:

Stage I
Stage II
Stage III
Stage IV

HER2 Positive Gastric Cancer Market by End-User:

Ambulatory surgery centres,
Hospitals and Specialty clinics
Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Parkinson’s Disease Therapeutic Market Poised for Steady Growth, Projected to Reach USD 6.7 Billion by 2034 at a 5.1% of CAGR

The Parkinson’s Disease Therapeutic market is on an upward trajectory, with significant growth anticipated in the coming decade. According to the latest market analysis, the market is expected to achieve a valuation of USD 4.3 billion in 2024 and is projected to expand to approximately USD 6.7 billion by 2034. This growth represents a compound annual growth rate (CAGR) of 5.1% over the next ten years.

The steady increase in market size reflects the growing demand for advanced therapeutic solutions and ongoing advancements in treatment options for Parkinson’s disease. As the global population ages and awareness of the disease increases, the market is set to experience robust expansion.

The steady increase in market size reflects the growing emphasis on developing innovative treatments and therapies for Parkinson’s disease. As research advances and new therapeutic options emerge, the market is expected to benefit from heightened investment in medical research and a stronger focus on addressing the needs of patients living with this neurodegenerative condition.

The market’s expansion underscores the ongoing commitment to improving patient outcomes through advanced therapies and enhanced treatment options. With continued innovation and a dedicated effort to address the challenges of Parkinson’s disease, the therapeutic market is poised for continued progress and growth.

According to the Parkinson’s Foundation, males are more likely than women to have Parkinson’s disease. Men were discovered to have a higher occurrence, and their risk was shown to be around 1.5 times higher than that of women. Most often, those over 60 are affected by it. A number of the symptoms of Parkinson’s disease can be alleviated with medication and other therapy methods including exercise. Drugs including safinamide, levodopa, benztropine, pramipexole, and selegiline are important therapy options for Parkinson’s disease patients.

Increasing pharmacological approvals for the Parkinson’s disease treatment are anticipated to stimulate market expansion throughout the anticipated time frame. For instance, the Japanese pharmaceutical and biotechnology company Kyowa Kirin Co., Ltd. reported in August 2019 that the NOURIANZ medication has received FDA clearance in the United States (istradefylline). It is used as an additional therapy to levodopa/carbidopa in adult patients with Parkinson’s disease who are having ‘OFF’ episodes (PD).

When a patient’s medications are not functioning effectively, it can lead to an increase in Parkinson’s disease (PD) symptoms including tremor and walking problems, which is known as an “off episode.” In the US, NOURIANZ (istradefylline), an antagonist of the adenosine A2A receptor, is used for Parkinson’s disease. The medication offers patients with Parkinson’s disease a brand-new non-dopaminergic once-daily oral treatment alternative. Such developments are expected to spur the global growth in the Parkinson’s disease market from 2023-2033.

Key Takeaways from the Market Study

The global Parkinson’s disease market is currently worth more than US$ 4.82 Billion.
In 2023, the Carbidopa-levodopa segment by drug class type is expected to take the dominant market share of 32%.
In 2023, considering the age type, the adult segment is predicted to gain a 21% market share.
The North American market for Parkinson’s disease is predicted to grow with a steady CAGR of 12.5% from 2023-2033.
The APAC for Parkinson’s disease is expected to grow with a steady CAGR of 12% during 2023-2033.

“The market is anticipated to expand as more drugs are approved for the treatment of Parkinson’s disease and as there is a robust pipeline of novel medications being developed for the condition.” comments a Future Market Insights analyst.

Competitive Landscape

Some of the top players in the global Parkison’s disease market are:

Sunovion Pharmaceuticals
Adamas Pharmaceuticals
Neurocrine Biosciences
Supernus Pharmaceuticals
Alectos Therapeutics
Kyowa Kirin
AbbVie
Integrative Research Laboratories AB
Annovis Bio Inc.
Cerevel Therapeutics
Biogen Inc.
Amneal Pharmaceuticals

Some of the recent developments in this domain are:

Biogen Inc. and Alectos Therapeutics signed an agreement in June 2022 to develop and market GBA2 inhibitors (AL01811), a possible therapy for Parkinson’s disease patients. This agreement grants Biogen worldwide rights to research, manufacture, and commercialize AL01811. They think they will be well-suited to assist bring AL01811 to patients who need it by combining Alectos’ experience in small-molecule therapies with Biogen’s worldwide development expertise in Parkinson’s disease. They are indeed energized by the prospect of using Biogen’s commercial skills to raise the standard of treatment in Parkinson’s disease as well as movement disorders in general.

More Valuable Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Parkinson’s disease market, presenting historical demand data (2018-2022) and forecast statistics from 2023 to 2033.

The study divulges essential insights on the market based on the parkinson’s disease market by type (juvenile parkinson disease, young-onset parkinson’s disease, idiopathic parkinson disease), by age (adult and pediatric), by diagnosis (CT Scan, MRI Scan, DaTSCAN-SPECT scan, PET Scan), by drug class (carbidopa-levodopa, carbidopa-levodopa infusion, dopamine agonists, monoamine oxidase b inhibitors, catechol o-methyltransferase inhibitors, anticholinergics, amantadine) and regions.

A Old Full Report Analysis Click Here

Key Segments Profiled in the Amyotrophic Lateral Sclerosis Industry Survey

Treatment:

Medication
Stem Cell Therapy
Others

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

Region:

North America
Latin America
Europe
Asia Pacific
MEA

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us: